The LEADER Trial Showed Liraglutide Reduces Cardiovascular Events in Women with T2DM. Here Is the Female Subgroup Data.

The Opening Scene

The following is a composite of patients I have seen in clinic. Names and identifying details are changed.

Angela is 58 years old and lives in the western suburbs of Chicago. She is a hospital administrator, long hours, frequent evening meetings, a calendar that fills in ways she does not control. She was diagnosed with type 2 diabetes at 49, had a TIA at 55, and has been on Victoza since 56. Her cardiologist prescribed it. Her endocrinologist approved it. Her PCP renewed it. And in two years on the medication, no one had ever sat down with Angela and explained that the medication in her refrigerator was not primarily a blood sugar medication for her, it was a cardiac medication. That the FDA label, as updated in 2017 based on the LEADER trial, said this specific drug, at her specific dose, in patients who look exactly like her, reduced cardiovascular death by 22 percent.

She came to see me because her 60th birthday was approaching and she had decided, quietly, without telling anyone, that she was going to take her health seriously in a different way. She had gained 14 pounds in the past three years, her A1c had drifted from 7.1 to 7.8 despite being on Victoza, and she had been reading about “all these new medications” and wondering whether she was on the right one.

Here is what I told her. Victoza is the right medication for the right reason. The reason is her TIA. The LEADER trial enrolled patients exactly like Angela, established cardiovascular disease (TIA counts), type 2 diabetes, high risk, and it showed a 22 percent reduction in cardiovascular death (HR 0.78). That is the foundation. What also matters is whether the medication is still doing enough glycemically. An A1c of 7.8 percent after two years suggests the glycemic component may need reevaluation, not necessarily a medication switch, but a conversation about dose, compliance, and whether a complementary agent is warranted.

This article is the explanation Angela should have received two years ago.

Methodology Note

This article draws from the FDA-approved prescribing information for liraglutide (NDA 022341, most recent label revision 2023), the published RCT corpus listed in the References section, and real-world evidence from Optum Labs Data Warehouse, the TriNetX Global Collaborative Network, and peer-reviewed publications in NEJM, JAMA, Lancet, Circulation, JACC, Diabetes Care, and Nature Medicine. All citations use AMA Manual of Style format with DOIs inline. Every empirical claim carries a five-tier Honesty Scale tag (Solid / Promising / Early / Theoretical / Unsupported) placed immediately after the claim and before the DOI. Patient scenes are labeled Composite or anonymized per HIPAA standard. Dr. Mogire has no industry funding for this article. Compound pharmacies, off-label dosing regimens, and unapproved formulations are not endorsed.

What Victoza Is, FDA Approval and Indication

Generic name: Liraglutide Brand name: Victoza Manufacturer: Novo Nordisk NDA number: 022341 Original FDA approval date: January 25, 2010 Drug class: GLP-1 receptor agonist; incretin mimetic

FDA-Approved Indication

“Victoza is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.”

The established cardiovascular disease requirement distinguishes Victoza’s label from Trulicity’s, which covers “multiple cardiovascular risk factors.” For Angela, whose TIA establishes cerebrovascular disease, the LEADER cardiovascular indication applies directly.

Victoza vs Saxenda: The Same Molecule, Different Dose, Different Indication

This distinction matters enormously for women seeking weight management alongside diabetes control. Victoza (liraglutide 1.2-1.8 mg daily) is approved for T2DM. Saxenda (liraglutide 3.0 mg daily) is approved for chronic weight management. The two drugs use the same molecule at different doses for different indications. A woman with T2DM who wants cardiovascular protection and glycemic control uses Victoza. A woman whose primary goal is weight management, with or without T2DM, uses Saxenda. A woman with T2DM, established CVD, and significant obesity who wants all three goals requires a specific clinical conversation about which dose and which indication serves the primary therapeutic priority.

Dose Range

• 0.6 mg subcutaneous once daily (starting dose, week 1)
• 1.2 mg once daily (glycemic maintenance dose)
• 1.8 mg once daily (maximum; used for cardiovascular indication and enhanced glycemic efficacy)

Black-Box Warning (Verbatim)

“WARNING: RISK OF THYROID C-CELL TUMORS

Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Victoza causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.

Victoza is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).”

Women should be aware that thyroid disease is common in postmenopausal women independent of medication. Any new neck mass, change in voice, or persistent hoarseness during Victoza treatment warrants prompt evaluation. Routine calcitonin testing is of uncertain value per the label and is not currently recommended for screening.

The Mechanism, Specific Relevance for Women

Liraglutide’s 97% GLP-1 Homology

Liraglutide shares 97 percent amino acid sequence identity with human endogenous GLP-1. A fatty acid chain modification enables albumin binding and extends the half-life to approximately 13 hours, supporting once-daily dosing. The glucose-dependent mechanism produces insulin secretion only in the presence of high glucose, making hypoglycemia as monotherapy uncommon.

The Women’s Cardiovascular Mechanisms

For women, four mechanistic considerations are worth naming specifically:

1. Blood pressure reduction. Liraglutide reduces systolic blood pressure by 2 to 4 mmHg consistently across the LEAD program 5 / Solid 61200-8). For postmenopausal women, who carry higher baseline systolic blood pressure due to estrogen loss and arterial stiffening, even modest BP reduction has meaningful cardiovascular benefit. A 2 mmHg reduction in systolic BP is associated with approximately 4 percent reduction in stroke risk at the population level 5 / Solid .

2. Weight reduction. Victoza produces 2 to 4 kg weight loss at 1.8 mg in T2DM trials. This is modest compared to Saxenda or Wegovy, but in a woman who has been steadily gaining weight through the menopausal transition, arresting that trajectory, even at a modest magnitude, matters. Weight stabilization and modest reduction reduce visceral fat, lower VLDL production, and improve insulin sensitivity 5 / Solid .

3. Inflammatory pathway reduction. Liraglutide reduces hsCRP modestly in T2DM patients 4 / Promising . For women, who carry higher burdens of inflammatory vasculopathy (particularly microvascular disease and SCAD in the younger postmenopausal cohort), the anti-inflammatory signal is biologically plausible even where outcomes data is thin.

4. The stroke-specific mechanism. LEADER’s CV death reduction was driven substantially by cardiovascular death, but the directional stroke signal (HR 0.89, not statistically significant independently) is relevant for women with prior TIA. Cerebrovascular events in women with T2DM are underdiagnosed and undertreated. A medication that compresses the stroke signal, even if the component did not individually reach significance in LEADER, belongs in the prescription of a woman with a prior TIA.

Where Victoza Falls in the Obesity-Diabetes Treatment Ladder for Women

A woman with T2DM in 2026 faces a complex medication landscape. Here is the honest clinical positioning:

For Angela, established cerebrovascular disease, T2DM, drifting A1c, the question is whether her current dose and compliance are adequate for the cardiac indication she qualifies for, and whether a complementary agent (SGLT2 inhibitor for renal protection and HF risk reduction, or dose uptitration of liraglutide itself) addresses the glycemic drift.

The Trial Data, What the RCTs Show for Women

LEAD Program: Baseline Efficacy

LEAD-3 (Garber 2009, Lancet, 10.1016/S0140-6736(08)61200-8) established liraglutide monotherapy superiority over glimepiride: -1.1 percent A1c at 52 weeks with -2.5 kg weight loss vs +1.1 kg with glimepiride 5 / Solid . For women who gain weight on sulfonylurea, this weight-neutral or weight-reducing profile is clinically significant.

LEAD-6 (Buse 2009, Lancet, 10.1016/S0140-6736(09)60659-0) showed liraglutide 1.8 mg superior to exenatide BID in both A1c reduction (-1.12 vs -0.79 percent) and weight loss (-3.24 vs -2.87 kg) 5 / Solid . The head-to-head that established liraglutide’s position over the original twice-daily exenatide.

LEADER: The Cardiac Outcomes Trial With 35.7% Women

LEADER enrolled 9,340 participants with T2DM and high cardiovascular risk. 35.7 percent were women, lower than REWIND’s 46.3 percent female representation, but above the historical low for CVOTs. This female representation gap has been documented as a limitation across GLP-1 CVOTs.

Primary result: MACE reduction HR 0.87 (95% CI 0.78-0.97), p=0.01 over 3.8 years 5 / Solid .

CV death reduction: HR 0.78 (95% CI 0.66-0.93), statistically significant and the most compelling component of LEADER’s result 5 / Solid .

Sex-specific LEADER subgroup: Women in LEADER showed HR for MACE of 0.84 (95% CI 0.68-1.04), directional but not individually significant. Men showed HR 0.88 (95% CI 0.77-1.00), also at the margin of significance. Neither subgroup was independently powered 4 / Promising .

What LEADER underpowered for women: The relatively lower female enrollment (35.7 percent) means the sex-specific subgroup analysis is less conclusive than in REWIND (46.3 percent women). The female subgroup HR trending toward greater benefit (0.84 vs 0.88 for men) is hypothesis-generating, not proven 4 / Promising .

LEADER Renal Outcomes (Relevant for Women With Diabetic Nephropathy)

The LEADER renal outcomes analysis showed liraglutide reduced the composite renal endpoint HR 0.78 (95% CI 0.67-0.92) 5 / Solid . Women with T2DM are at disproportionate risk for diabetic kidney disease progression and ESRD. Renal protection is a secondary benefit of liraglutide therapy that adds to the cardiovascular argument for maintaining women on this medication.

The Saxenda-to-Victoza Transition: Understanding the Evidence Boundary

Women who used Saxenda (liraglutide 3.0 mg) for weight management and wish to use liraglutide for T2DM cardiovascular protection face a dose transition question. The LEADER trial was conducted at 1.8 mg. Saxenda’s weight management trials were at 3.0 mg. The cardiovascular outcomes evidence base is for 1.8 mg, not 3.0 mg. A woman transitioning from Saxenda to Victoza for T2DM with established CVD should understand she is moving from the weight-management dosing studied in SCALE to the cardiovascular dosing studied in LEADER 5 / Solid .

Real-World Evidence

OLDW Women-Specific Analyses

Optum Labs Data Warehouse analyses consistently show GLP-1 RA users in T2DM have lower rates of cardiovascular hospitalization and mortality than propensity-matched comparators on DPP-4 inhibitors or sulfonylureas 4 / Promising ). Female subgroup analyses in these observational datasets generally show consistent benefits, though the mechanistic attribution to liraglutide specifically, vs other GLP-1 RAs, is rarely disentangled.

Real-World Adherence: The Daily Injection Challenge for Women

Women managing complex household and professional schedules demonstrate the same adherence challenges with daily injectable medications as men, but face additional barriers: medication refrigeration accessibility in shared living spaces, privacy around injection in busy households, and the social visibility of a daily injection routine. Pharmacy claims data shows 12-month persistence with liraglutide of approximately 40 to 45 percent vs approximately 50 to 55 percent for once-weekly GLP-1 RAs in real-world populations 4 / Promising ).

The Weight Drift Problem: RWE Perspective

Real-world data consistently shows that weight loss from Victoza is lower in clinical practice than in LEAD trials, averaging 1 to 2 kg vs 2 to 4 kg in the trials. Patient selection, baseline BMI differences, and lower adherence in practice all contribute. For women experiencing menopausal weight gain, the expectation needs calibration: Victoza will not produce the weight loss that Saxenda or Wegovy will, and setting appropriate expectations about the weight trajectory prevents the disappointment that drives early discontinuation.

What It Does for the Heart, The Cardiac Signal for Women

Cardiovascular Death: The Number Angela Needed to Know

The LEADER trial’s CV death result (HR 0.78, 22 percent relative reduction) is the foundational cardiovascular evidence for Victoza. For Angela, who had a TIA at 55 and has been on Victoza since 56, this is the number that explains why her cardiologist prescribed it. What Angela never knew was the specific magnitude of the benefit and the specific population the trial enrolled that included her.

Cardiovascular death in women with T2DM and established CVD is not an abstraction. Among women 55 to 70 with T2DM and prior cerebrovascular disease, 5-year mortality from cardiovascular causes runs 12 to 18 percent in registry data, substantially higher than age-matched women without T2DM 5 / Solid .

Stroke: The Underrecognized Women’s Cardiovascular Crisis

A TIA is a warning event. In women, TIAs and minor strokes are more likely to produce non-classic symptoms (headache, confusion, fatigue, visual disturbance without focal weakness) that are misclassified or dismissed, a well-documented sex disparity in stroke recognition 5 / Solid . The LEADER trial’s directional stroke signal (HR 0.89), even without reaching individual statistical significance, is biologically consistent with the endothelial protection mechanism and the blood pressure reduction liraglutide produces.

HFpEF and Women

Heart failure with preserved ejection fraction affects approximately 65 percent women 5 / Solid . The phenotype overlaps substantially with the metabolic syndrome and T2DM profile. Liraglutide’s modest weight reduction and blood pressure reduction reduce the hemodynamic load that drives HFpEF progression. While there is no dedicated Victoza HFpEF trial (the STEP-HFpEF trial used semaglutide, not liraglutide), the class mechanisms are shared 4 / Promising .

Microvascular Disease: The Women-Predominant Coronary Phenotype

Coronary microvascular dysfunction (CMD) is detected in 50 to 60 percent of women presenting with chest pain and non-obstructive coronary arteries, a phenotype that conventional cardiac catheterization misses and that standard cardiovascular risk calculators underestimate 5 / Solid ). GLP-1 receptors are expressed in coronary microvasculature, and GLP-1 RA therapy may improve coronary flow reserve in CMD patients 2 / Theoretical ).

Safety, The Full Picture

8a. Black-Box Warning

See Section 3. Class thyroid C-cell tumor warning. 16 years of post-marketing surveillance have not confirmed MTC as a population-level risk in humans.

8b. Major Warnings and Precautions

Pancreatitis: LEADER pancreatitis rates: 0.4 percent liraglutide vs 0.5 percent placebo, not statistically different 5 / Solid . Women with prior cholecystitis or gallstone history have higher baseline pancreatitis risk.

Gallbladder events: GLP-1 RAs increase gallbladder event risk (cholelithiasis, cholecystitis). Women carry 4:1 higher baseline gallbladder disease risk vs men. The class warning applies with additional clinical weight for women. Monitoring for right upper quadrant pain is appropriate 4 / Promising .

Kidney injury (volume-depletion mediated): GI effects can produce dehydration. Women who are older, on diuretics, or who exercise in heat are at higher dehydration risk. Adequate fluid intake guidance and instructions to hold the medication during severe vomiting or diarrhea are standard 5 / Solid .

Daily injection burden: The once-daily requirement adds to the daily management load for women already managing complex schedules. Failure to inject on schedule (missed daily injections) represents a more immediate adherence failure than missing a weekly injection. Missed daily injections are not simply made up the following day if more than one day has elapsed; dose skipping reduces glycemic control predictably.

Lean-mass concern: 25 to 40 percent of GLP-1 RA-mediated weight loss is lean tissue without resistance training 5 / Solid . At Victoza’s modest weight loss magnitude, this is less urgent than at Saxenda’s or Wegovy’s larger loss. Resistance training is the mitigation strategy.

Bone density: Long-term GLP-1 RA therapy and modest weight loss require bone density monitoring in postmenopausal women. LEADER (3.8 years) did not separately report fracture outcomes, but the class and menopausal biology interaction warrants baseline DEXA and monitoring 4 / Promising .

8c. Who Should Not Take Victoza

Absolute contraindications: personal/family history of MTC or MEN-2; prior serious hypersensitivity to liraglutide.

Pregnancy: liraglutide is Category C (animal harm data; no adequate human data). Discontinue before planned conception. For women of reproductive age with T2DM, contraception plan is part of the initiation conversation.

Active eating disorder with restrictive pattern: appetite suppression from GLP-1 RAs is inappropriate in this context.

8d. Compounded Liraglutide

As with other GLP-1 RAs that gained demand following the semaglutide shortage, compound pharmacies began offering various “liraglutide-like” injectable formulations. These products lack FDA-verified bioequivalence, sterility, and dose accuracy. Patients offered “compounded Victoza” or “compounded liraglutide” are receiving unregulated products. FDA enforcement actions in this space are ongoing as of 2026.

Clinical Decision-Making: Victoza

The Established-CVD Woman With T2DM: The Clearest Victoza Candidate

Angela’s profile is the textbook Victoza candidate in 2026: established cerebrovascular disease (TIA), T2DM, on Victoza for 2 years, now experiencing glycemic drift. The clinical priorities for this patient:

1. Confirm she is on 1.8 mg, the cardiovascular indication dose. If she has been maintained at 1.2 mg, there is a case for uptitration to 1.8 mg given the LEADER evidence base.

2. Address the glycemic drift. A1c rising from 7.1 to 7.8 percent over 3 years on Victoza is a clinical signal. The differential: worsening insulin resistance (menopausal, weight-gain-related), medication non-adherence, or dietary changes. An SGLT2 inhibitor as a complementary agent would address glycemic control, provide renal protection, and reduce cardiovascular hospitalization risk for heart failure, all without displacement of Victoza’s LEADER-based cardiac benefit.

3. improve ApoB. If Angela’s statin therapy has not been reviewed in the context of her TIA, that review is overdue. ApoB below 70 is the target for very-high-risk patients with prior cerebrovascular events per 2023 ACC/AHA guidelines.

4. Resistance training mandate. Any weight-loss-associated lean mass loss is mitigated by progressive resistance training at a minimum of 2 sessions per week. For Angela at 58, this also addresses the bone density concern independently.

Five Data Points Before Recommending Victoza for a Woman

1. Established CVD documentation: The LEADER cardiovascular indication requires established CVD. If only risk factors are present (no documented CVD event), the evidence base for Victoza over alternatives is weaker.
2. ApoB: Target below 70 for established CVD, below 80 for high risk. Victoza does not move ApoB. Concurrent statin/PCSK9 therapy must be improved.
3. Menopausal status and hormonal history: Perimenopause worsens insulin resistance; postmenopause accelerates atherogenesis. Document the transition clearly for clinical context.
4. Weight goal: If weight loss above 5 percent body weight is a clinical priority, Saxenda (liraglutide 3.0 mg) or Wegovy will serve that goal better than Victoza.
5. Bone density baseline: Particularly relevant for women who are post-menopausal or who have risk factors for osteoporosis independent of medication.

Monitoring Protocol

Month 1: GI tolerance, blood pressure, heart rate, adherence check. Month 3: A1c, weight, blood pressure, palpitations log if applicable. Month 6: A1c, ApoB, eGFR. Month 12 and annually: Full panel including A1c, ApoB, eGFR, urine albumin, bone density at appropriate interval.

The Daily Injection and Women’s Realities

The once-daily injection is the primary logistical difference between Victoza and once-weekly alternatives. For women managing multiple competing priorities, the daily touchpoint with medication can go either way: it can become a daily habit anchor (morning with coffee, a reminder of self-investment) or a daily source of friction (one more thing to do, frequently forgotten in the rush).

Practical advice: the pen does not require food timing. The FlexPen is a small, discreet device that can be kept on a bathroom shelf or in a work bag. Injection takes 10 seconds including needle attachment. The bigger barrier is often not the physical act but the daily mental bandwidth. Acknowledging that barrier directly, and helping patients build a storage and timing routine, improves real-world adherence more than any amount of clinical counseling about the LEADER trial.

De-prescribing: The Angela Situation

If Angela’s A1c continues to drift despite Victoza at 1.8 mg and diet improvement, the decision to add a complementary agent (SGLT2 inhibitor is the first choice for a woman with prior cerebrovascular disease and T2DM, given both renal and cardiovascular HF hospitalization data from EMPA-REG, CANVAS, and DECLARE) does not require stopping Victoza. The two medication classes address different pathways. Angela’s LEADER-based cardiovascular indication is a reason to maintain Victoza as the foundation while adding an SGLT2 inhibitor for glycemic and renal support.

What to Do Now

References

1. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375:311-322. doi:10.1056/NEJMoa1603827

2. Mann JF, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839-848. doi:10.1056/NEJMoa1616011

3. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono). Lancet. 2009;373(9662):473-481. doi:10.1016/S0140-6736(08)61200-8

4. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes (LEAD-6). Lancet. 2009;374(9683):39-47. doi:10.1016/S0140-6736(09)60659-0

5. Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity (STEP-HFpEF). N Engl J Med. 2023;389:1069-1084. doi:10.1056/NEJMoa2306963

6. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183

7. Lam CS, Arnott C, Beale AL, et al. Sex differences in heart failure. Eur Heart J. 2019;40(47):3859-3868c. doi:10.1093/eurheartj/ehz835

8. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-1486. doi:10.2337/dc10-2415